Thumbnail

DIABETIC FOOT ULCERS MARKET - PIPELINE INTELLIGENCE, 2020

Looking to buy the report?

Introduction

Diabetic foot ulcers are considered a major complication of diabetes mellitus, and probably the major component of diabetic foot syndrome. Diabetic foot ulcers have a considerable negative impact on patients’ lives, and are highly susceptible to infection, leading all too often to amputation. Diabetic foot ulcers represent a huge risk to a patient’s quality of life, escalating wound/infection management and costs, and accounting for a large proportion of all national healthcare budgets.

Diabetes is one of the serious chronic diseases that need attention. According to a research article by Bakker et al, it is estimated that approximately 15% of all people with diabetes will be affected by a foot ulcer during their lifetime, and, in fact, 1 in 4 people with diabetes will develop at least one ulcer post-diagnosis. All these factors are contributing to the impact of diabetic nephropathy, across the globe.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.

Diabetic Foot Ulcers Clinical Trial Analysis by Phase and Status

  • The clinical trial analysis for diabetic foot ulcers indicates that there are around XX number of trials under various phases
  • Phase X trials accounted for the majority share
  • The trial data analysis suggests a number of ongoing trials, as well as ones that have been terminated

Diabetic Foot Ulcers Clinical Trials Analysis, by Geography

  • By geography, the scope of the report covers the regional assessment for clinical trials, globally. It covers concise information regarding registered clinical trials in different countries, across several developed and emerging markets
  • The major driving factor for the market is the rising number of diabetic cases across the globe. According to the International Journal of Advances in Medicine, by 2030, approximately 79.4 million people will have diabetes. As people who with diabetes are at risk of getting foot ulcers, this is a major driving factor

Key Sponsors in Diabetic Foot Ulcers Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies, and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.

Reasons to buy the Report

This report will help you to understand

  • The number of clinical trials that are being conducted worldwide
  • The key products under development (Phase I, Phase II, and Phase III)
  • The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.)
  • The average recruitment size in trials
  • Key deals between institutions and industries
  • Insights on regional- and country-level data
  • Dormant and discontinued studies across the category
  • Information on key sponsors and profiles
  • Protocol and design comparisons, to generate the best solution for your product development strategy

1. Introduction

2. Research Methodology

3. Disease Epidemiology and Trends

4. Healthcare Expenditure and R&D Trends

5. Executive Summary

6. Clinical Trials Segmentation by Phase

                6.1 Phase-III Product Candidates

                6.2 Phase-II Product Candidates

                6.3 Phase-I Product Candidates

7. Clinical Trials, Segmentation by Status

                7.1 Suspended

                7.2 Terminated

                7.3 Withdrawn

                7.4 Ongoing

                7.5 Completed

                7.6 Others

8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)

                8.1. By Clinical Phase and Molecule Type

                8.2. By Clinical Phase and Route of Administration

                8.3 By Sponsor/Collaborator/Institutions

                8.4 By Geography

9. Market Updates

10. Key Sponsor Profiles

11. Sources and Disclaimer

12. About Mordor Intelligence

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?

Email

Message

By submitting, you confirm that you agree to our privacy policy